Combination Chemotherapy in Treating Patients With Extensive-Stage Small Cell Lung Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug and giving them in different ways may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining topotecan, carboplatin, and etoposide in treating patients who have extensive-stage small cell lung cancer.
Checked against the public recordLast updated Sep 9, 2021 · Source: ClinicalTrials.gov
What this study is about
- Purpose
- Treatment
- Study type
- Interventional
- Phase
- Phase 2
- Sponsor
- Wake Forest University Health Sciences
- Interventions being studied
- Drug: carboplatin; Drug: etoposide; Drug: topotecan hydrochloride; Radiation: radiation therapy
How this study is categorized
These labels come from structured fields and exact terms in the public record.
Who may be able to participate
DISEASE CHARACTERISTICS: * Histologically or cytologically confirmed extensive stage small cell lung cancer * Measurable or evaluable disease * Pleural effusions allowed, but not considered measurable or evaluable disease * Brain metastases allowed provided neurologically stable at study entry PATIENT CHARACTERISTICS: Age: * 18 and over Performance status: * ECOG 0-2 Life expectancy: * More than 2 months Hematopoietic: * Absolute neutrophil count at least 1,500/mm\^3 * Platelet count at least 100,000/mm\^3 Hepatic: * Bilirubin no greater than 1.5 mg/dL Renal: * Creatinine no greater than 1.5 mg/dL Other: * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * Able to swallow capsules * No concurrent or prior malignancy within the past 5 years except inactive nonmelanomatous skin cancer or carcinoma in situ of the cervix * No other serious medical or psychiatric illness that would preclude study compliance PRIOR CONCURRENT THERAPY: Biologic therapy: * Not specified Chemotherapy: * No prior chemotherapy Endocrine therapy: * Not specified Radiotherapy: * Prior radiotherapy for brain metastasis allowed * No other prior radiotherapy * No other concurrent radiotherapy Surgery: * Not specified
Important: This is the sponsor’s public criteria, not a determination of eligibility. The study team must review your individual situation.
U.S. locations
- Southeastern Medical Oncology CenterGoldsboro, North Carolina
- Comprehensive Cancer Center at Wake Forest UniversityWinston-Salem, North Carolina
- CCOP - GreenvilleGreenville, South Carolina
- CCOP - Upstate CarolinaSpartanburg, South Carolina
- MBCCOP - Massey Cancer CenterRichmond, Virginia
Source and freshness
Processed from ClinicalTrials.gov. Last public update: Sep 9, 2021. Always confirm current availability with the study team.